Sublingual Dexmedetomidine vs Placebo and Acute Agitation Associated With Bipolar Disorder

JAMA. 2022 Jul 12;328(2):213. doi: 10.1001/jama.2022.8346.
No abstract available

Publication types

  • Comment

MeSH terms

  • Administration, Sublingual
  • Antipsychotic Agents* / administration & dosage
  • Antipsychotic Agents* / therapeutic use
  • Bipolar Disorder* / complications
  • Bipolar Disorder* / drug therapy
  • Dexmedetomidine* / administration & dosage
  • Dexmedetomidine* / therapeutic use
  • Humans
  • Hypnotics and Sedatives* / administration & dosage
  • Hypnotics and Sedatives* / therapeutic use
  • Psychomotor Agitation* / drug therapy
  • Psychomotor Agitation* / etiology

Substances

  • Antipsychotic Agents
  • Hypnotics and Sedatives
  • Dexmedetomidine